Chemomab Therapeutics Ltd

詳細情報 Chemomab Therapeutics Ltd 企業名

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

企業情報

企業コードCMMB

会社名Chemomab Therapeutics Ltd

上場日Aug 14, 2012

最高経営責任者「CEO」Dr. Adi Mor, Ph.D.

従業員数16

証券種類Depository Receipt

決算期末Aug 14

本社所在地Kiryat Atidim, Building 7

都市TEL AVIV-YAFO

証券取引所NASDAQ Capital Market Consolidated

国Israel

郵便番号6158002

電話番号972773310156

ウェブサイトhttps://www.chemomab.com/

企業コードCMMB

上場日Aug 14, 2012

最高経営責任者「CEO」Dr. Adi Mor, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Sigal Fattal, CPA

Chief Financial Officer

639.00

-82.96%

Dr. Nissim Darvish, M.D. Ph.D.

Independent Chairman of the Board

300.00

--

Mr. Neil Cohen

Independent Director

--

Dr. Alan Charles Moses, M.D.

Independent Director

--

Dr. Claude Nicaise, M.D.

Independent Director

--

Ms. Irina Koffler

Investor Relations

--

Dr. Adi Mor, Ph.D.

Chief Executive Officer, Director

--

Mr. Jack Lawler

Chief Development Officer

--

Dr. David M. Weiner, M.D.

Interim Chief Medical Officer

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Sigal Fattal, CPA

Chief Financial Officer

639.00

-82.96%

Dr. Nissim Darvish, M.D. Ph.D.

Independent Chairman of the Board

300.00

--

Mr. Neil Cohen

Independent Director

--

Dr. Alan Charles Moses, M.D.

Independent Director

--

Dr. Claude Nicaise, M.D.

Independent Director

--

Ms. Irina Koffler

Investor Relations

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Tue, Aug 19

株主統計

種類

株主統計

比率

Otto (Erik)

8.17%

Morgan Stanley & Co. LLC

7.80%

Apeiron Investment Group Ltd

5.47%

Rivendell Investments 2017-9 LLC

5.36%

OrbiMed Advisors, LLC

4.55%

他の

68.66%

株主統計

比率

Otto (Erik)

8.17%

Morgan Stanley & Co. LLC

7.80%

Apeiron Investment Group Ltd

5.47%

Rivendell Investments 2017-9 LLC

5.36%

OrbiMed Advisors, LLC

4.55%

他の

68.66%

種類

株主統計

比率

Individual Investor

11.37%

Research Firm

7.97%

Family Office

5.47%

Corporation

5.36%

Hedge Fund

4.60%

Private Equity

4.55%

Investment Advisor

3.14%

Investment Advisor/Hedge Fund

0.19%

他の

57.36%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

36

5.04M

26.29%

-928.14K

2025Q1

38

6.66M

34.89%

+231.83K

2024Q4

41

7.89M

41.83%

+519.06K

2024Q3

37

7.12M

38.75%

+430.17K

2024Q2

36

5.24M

33.24%

-261.90K

2024Q1

39

5.24M

33.39%

-405.62K

2023Q4

41

5.39M

34.50%

+2.72K

2023Q3

43

5.63M

49.23%

-777.20K

2023Q2

42

5.63M

49.23%

-912.41K

2023Q1

44

6.00M

54.09%

-854.86K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Otto (Erik)

1.16M

6.03%

+1.16M

--

Nov 21, 2024

Morgan Stanley & Co. LLC

117.16K

0.61%

+12.76K

+12.22%

Mar 31, 2025

Apeiron Investment Group Ltd

1.13M

5.91%

+404.86K

+55.68%

Dec 31, 2024

Rivendell Investments 2017-9 LLC

1.11M

5.78%

--

Dec 31, 2024

OrbiMed Advisors, LLC

131.27K

0.69%

-1.61M

-92.46%

Jun 23, 2025

Sphera Funds Management Ltd.

900.43K

4.7%

-314.15K

-25.86%

Mar 31, 2025

Yelin Lapidot Provident Funds Management Ltd

578.29K

3.02%

-165.84K

-22.29%

Mar 31, 2025

Mor George (Adi)

317.07K

1.65%

--

Dec 31, 2024

Ikarian Capital LLC

213.05K

1.11%

--

Mar 31, 2025

George (Kobi)

200.24K

1.04%

-50.91K

-20.27%

Dec 31, 2024

詳細を見る

2.650USD

Chemomab Therapeutics Ltd

2.650

概要

企業名

金融

分析